Found vs. IVIM Health: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, IVIM Health is the cheaper program at $278 a month all-in versus Found's $289 — a gap of $11 a month, $132 a year, at the 10 mg maintenance basis. Found: $289 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $169/mo (12-month plan paid up front). IVIM Health: $278 a month all-in at the 10 mg maintenance basis, dose-scaled from a $208 entry, including the mandatory $75/mo membership. Prepaid terms reorder things: Found at $169/mo (12-month plan paid up front) — paid up front, with the regulatory-era caveat that locked-in months deserve a read of the refund terms first.

Semaglutide pricing

On semaglutide, IVIM Health wins at $224 versus $289 all-in — $65/mo apart. Found: Semaglutide runs $289 a month all-in at the standing rate ($169 on intro/plan terms). IVIM Health: Semaglutide runs $224 a month all-in at the standing rate ($149 on intro/plan terms).

Transparency

Found: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. IVIM Health: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Found: none month-to-month; prepaid terms for lowest rate; membership recurs; prepaid terms are paid up front. IVIM Health: membership mandatory for duration; membership mandatory; $75/mo membership recurs until cancelled.

The gap, compounded over time

Here is what the $11 monthly spread between these two actually buys back over a treatment course — one month, $11; six months, $66; a year, $132; two years of maintenance, $264. Only Found publishes a prepaid tier ($169/mo effective), which undercuts even IVIM Health's standing $278 by $1,308/year — flexibility versus committed savings, cleanly posed. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

Maintenance therapies deserve maintenance math: over two years at standing rates, Found bills $6,936 and IVIM Health $6,672, a spread of $264 for the same molecule at the same 10 mg basis. If prepaid terms held across both years, Found's $169 effective would total $4,056 — $2,616 under even the cheaper standing plan, with the standing caveat that two years of locked funds in this regulatory climate is a real bet, not a rounding choice. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

Put both dose ladders on the same axis and the structures argue for themselves: Found holds $289 on every rung (four-month titration: exactly $1,156); IVIM Health scales $208 → ~$278 by 10 mg (titration lands between $832 and $1,112). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $289 at Found versus $208 at IVIM Health for the 2.5 mg rung — an early edge that holds once the ladder climbs. The settled 10 mg maintainer — the buyer our basis is built for — pays $3,336/year at IVIM Health against $3,468 at the other: $132 of annual daylight for the same molecule and dose. The committed prepayer does best at Found: $169/month effective, $2,028/year, funds up front, refund terms first.

The semaglutide board

IVIM Health takes the semaglutide board too at $224 versus $289 all-in — a $65/month, $780/year spread. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. Found's ranked figure is $289, with no membership to add; IVIM Health's ranked figure is $278 ($203 medication + $75 mandatory membership). 2 · Maintenance basis. Found is dose-flat, so its entry and 10 mg figures coincide; IVIM Health scales from $208 to $278, and the 10 mg figure is the one ranked. 3 · Terms separated. Found: standing $289, prepaid $169 effective (12-month plan paid up front); IVIM Health: standing $278, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Found: third-party-reported, read 2026-08-05; IVIM Health: source-verified, read 2026-08-05. 5 · Pharmacy weighed. Found names no pharmacy; IVIM Health names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Found: no membership — the medication figure is the billed figure; prepaid 12-month plan paid up front at $169/mo effective; membership recurs; prepaid terms are paid up front; commitment: none month-to-month; prepaid terms for lowest rate. IVIM Health: a mandatory $75/mo membership folded into our all-in figure; membership mandatory; commitment: membership mandatory for duration. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Found carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. IVIM Health carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Moving from Found to IVIM Health (or back) is administratively unglamorous: complete the new program's intake, let its prescriber issue a fresh prescription to its pharmacy, and cancel the old subscription in writing — prescriptions don't transfer between telehealth programs, and neither do prepaid balances, which is the quiet reason month-to-month terms are worth their premium.

Refills, shipping, and the week-to-week reality

The unglamorous layer — how the medication actually reaches you and stays on schedule — splits like this: Found: shipping included; consultation included; async visit model. IVIM Health: shipping included; consultation video visit included in membership; video visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Found if you want a price that survives titration; you'll prepay for the $169 effective rate; you want the insurance paperwork done for you; you refuse membership fees on principle. Pick IVIM Health if the $11/month tirzepatide saving is the point; the semaglutide line is cheaper here. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

The dataset's bench is deep; the closest verified third options to this matchup's price band are Mochi Health at $278 (flat, $79 membership included, named pharmacy); ShedRx at $289 (dose-scaled, no membership); OrderlyMeds at $299 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $2,052/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

On the numbers alone, IVIM Health is the cheaper tirzepatide program by $11/mo and it doesn't trade that price for opacity ; Found's case rests on insurance navigation. Both records, with dates and sources, live in the pricing database.